+

WO1994022309A1 - Inhibiteurs synthetiques de la metalloprotease de matrice et utilisations - Google Patents

Inhibiteurs synthetiques de la metalloprotease de matrice et utilisations Download PDF

Info

Publication number
WO1994022309A1
WO1994022309A1 PCT/US1994/003600 US9403600W WO9422309A1 WO 1994022309 A1 WO1994022309 A1 WO 1994022309A1 US 9403600 W US9403600 W US 9403600W WO 9422309 A1 WO9422309 A1 WO 9422309A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
group
substituted
inhibitor
aryl
Prior art date
Application number
PCT/US1994/003600
Other languages
English (en)
Inventor
Richard Edward Galardy
Damian Grobelny
Gregory Scott Schultz
Original Assignee
Glycomed Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycomed Incorporated filed Critical Glycomed Incorporated
Priority to EP94913345A priority Critical patent/EP0692931A4/fr
Priority to AU65542/94A priority patent/AU6554294A/en
Priority to JP6522412A priority patent/JPH08511509A/ja
Publication of WO1994022309A1 publication Critical patent/WO1994022309A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Definitions

  • Serial No. 07/817,039 filed January 7, 1992, and a continuation-in-part of United States patent application Serial No. 07/881,630 filed May 12, 1992.
  • Serial No. 07/817,039 is also a continuation-in-part of United States patent application Serial No. 07/747,752 filed August 20, 1991 and United States patent application Serial No. 07/747,752 filed August 20, 1991, both of which are continuations-in-part of United States patent application Serial No. 07/615,798 filed November 21, 1990.
  • Serial No. 07/881,630 is a continuation of U. S. patent application Serial No. 07/616,021 filed November 21, 1990.
  • the invention relates to synthetic compounds that are inhibitors of matrix metalloproteases, and certain medical applications thereof.
  • Collagenase and related enzymes are important in mediating the symptomology of a number of diseases, including rheumatoid arthritis (Mullins, D.E., et al., Biochim Biophys Acta (1983) 695:117-214); the metastasis of tumor cells (ibid., Broadhurst, M.J., et al., EP application 276436 (1987), Reich, R., et al., Cancer Res (1988) 48:3307- 3312); and various ulcerated conditions. Ulcerative conditions can result in the cornea as the result of alkali burns or as a result of infection by Pseudomonas aeruginosa.
  • inhibitors to this enzyme In view of the involvement of collagenase in a number of disease conditions, attempts have been made to prepare inhibitors to this enzyme. A number of such inhibitors are disclosed in EP applications 126,974 (published 1984) and 159,396 (published 1985) assigned to G.D. Searle. These inhibitors are secondary amines which contain oxo substituents at the 2-position in both substituents bonded to the amino nitrogen.
  • thermolysin hydroxamic peptide derivatives described by Nishino, N., et al., Biochemistry (1979) 18:4340-4347; Nishino, N., et al., Biochemistry (1978) 17:2846-2850.
  • Tryptophan is also known to be therapeutic in various conditions, some of which may involve collagenase (see, for example, JP 57/058626; U.S. 4,698,342; 4,291,048). Also, inhibitors of bacterial collagenases have been disclosed in U.S. 4,558,034.
  • the invention compounds add to the repertoire of agents available for the treatment of conditions and diseases which are characterized by unwanted activity by the class of proteins which destroy structural proteins and designated "matrix metalloprotease" herein.
  • Angiogenesis is defined as the growth of new blood vessels, in particular, capillaries.
  • the ingrowth of such capillaries and ancillary blood vessels is essential for tumor growth and is thus an unwanted physiological response which encourages the spread of malignant tissue and metastases.
  • Inhibition of angiogenesis is therefore envisioned as a component of effective treatment of malignancy.
  • Neovascularization of the eye is a major cause of blindness.
  • proliferative diabetic retinopathy results from diabetes; blindness can also be caused by neovascular glaucoma.
  • Inhibition of angiogenesis is useful in treating these conditions also.
  • Actinonin is an antibiotic produced by a particular strain of Streptomyces and is a modified peptide structure.
  • the methods and compositions of the invention are preferably utilized for preventing or treating certain diseases that have as their underlying cause the activation and/or the expression of unwanted matrix metalloprotease activity.
  • diseases include skin disorders, keratoconus, restenosis, wounds, ulcers, particularly of the cornea or mouth, or those disease states that are benefitted by uncontrolled angiogenesis.
  • the invention is directed to a method for treating cancer, preferably by inhibiting angiogenesis which facilitates or is required for the growth and spread of cancer throughout a patients body.
  • Figure 1 shows light microscopic photographs of mouse skin exposed to PdiBu (panel A), or PdiBu and compound 5A (panel B) and stained with hematoxylin and eosin three days latter.
  • Figure 2 shows that the protease levels present in mastectomy fluid samples collected on days 1 to 7 after surgery were an average of 0.75 ⁇ 0.06 ⁇ g equivalents of collagenase/ml of wound fluid.
  • Figure 3 compares the protease levels present in mastectomy wound fluids collected from closed (collected on different days post operation), open, or chronic wounds. Note that closed wounds exhibited marginal protease activity, while open wound fluid contained an average protease level of 199 ⁇ 59 ⁇ g/ml, and fluids collected from chronic wounds contained an average protease level of 125 ⁇ 95 ⁇ g/ml.
  • Figure 4 shows the effect of three protease inhibitors on the protease activity of chronic wound fluid.
  • Compound 5A very effectively inhibited proteolytic degradation of Azocoll (approximately 96% of initial proteolytic activity) at final concentrations of 40 ⁇ g/ml (100 ⁇ M) or 4 ⁇ g/ml (10 ⁇ M).
  • EDTA a nonspecific inhibitor of metalloproteinases, also effectively reduced protease activity, approximately 96%.
  • PMSF a nonspecific inhibitor of serine proteases, reduced proteolytic activity approximately 65% at a concentration of 500 ⁇ M.
  • Figure 5 shows the effects of the inhibitors, compound 5A, PMSF and EDTA on protease activity present in open and chronic wounds.
  • Compound 5 A and EDTA were very effective inhibitors while PMSF did not significantly reduce the proteolytic activity of the wound fluids.
  • Figure 6 shows the effects of compound 5 A, S1209, UL001, MP506, and EDTA on the proteolytic degradation of Azocoll by wound fluids.
  • Figure 7 shows the effects of the inhibitors GM6001, GM1339, GM1489 and S1209 on protease activity present in chronic wound fluid.
  • the inhibitory compounds of the invention are synthetic inhibitors of mammalian matrix metalloproteases.
  • Matrix metalloproteases include without limitation human skin fibroblast collagenase, human skin fibroblast gelatinase, human neutrophil collagenase and gelatinase, and human stromelysin. These are zinc-containing metalloprotease enzymes, as are the angiotensin-converting enzymes and the enkephalinases.
  • “mammalian matrix metalloprotease” means any zinc-containing enzyme found in mammalian sources that is capable of catalyzing the breakdown of collagen, gelatin or proteoglycan under suitable assay conditions.
  • candidate compounds to inhibit matrix metalloprotease activity can, of course, be tested in the assays described above.
  • Isolated matrix metalloprotease enzymes can be used to confirm the inhibiting activity of the invention compounds, or crude extracts which contain the range of enzymes capable of tissue breakdown can be used.
  • assay of inhibition activity can be conducted as follows. Inhibitors may be assayed against crude or purified human skin fibroblast collagenase using the synthetic thiol ester substrate at pH 6.5 exactly as described by Kortylewicz & Galardy, J Med Chem (1990) 33:263-273, at a collagenase concentration of 1-2 nM. The candidate inhibitors are tested for their ability to inhibit crude collagenase and gelatinase from human skin fibroblasts, crude collagenase and gelatinase from purulent human neutrophil in this assay. The results may be set forth in terms of Ki, i.e., the calculated dissociation constant for the inhibitor complex with enzyme.
  • Ki values for effective inhibitors are ⁇ 500 nM for purified enzyme in this assay.
  • excellent inhibitors show Ki values of ⁇ 10 nM.
  • Assays for inhibition of human stromelysin are conducted as described by Teahan, J., et al., Biochemistry (1989) 20:8497-8501.
  • the synthetic compounds that are successful in these assays for mammalian matrix metalloprotease inhibition are generally small molecules containing at least one amide bond and have a variety of sidechain substituents. Examples of such compounds known in the art are given, as set forth above, in EP application 423,943, incorporated herein by reference.
  • R 3 is H or alkyl (1-4C);
  • R 4 is fused or conjugated unsubstituted or substituted bicycloaryl methylene; n is 0, 1 or 2;
  • n 0 or 1
  • X is OR 5 or NHR 5 , wherein R 5 is H or substituted or unsubstituted alkyl (1-12C), aryl (6-12C), aryl alkyl (6-16C); or
  • X is an amino acid residue or amide thereof
  • X is the residue of a cyclic amine or heterocyclic amine
  • R 6 is H or lower alkyl (1-4C) and R 7 is H, lower alkyl (1-4C) or an acyl group, and
  • R 3 is H or alkyl (1-4C);
  • R 4 is fused or conjugated unsubstituted or substituted bicycloaryl methylene; n is 0, 1 or 2;
  • n 0 or 1
  • X is OR 5 or NHR 5 , wherein R 5 is H or substituted or unsubstituted alkyl (1-12C), aryl (6-12C), aryl alkyl (6-16C); or
  • X is an amino acid residue or amide thereof
  • X is the residue of a cyclic amine or heterocyclic amine
  • Y is selected from the group consisting of R 7 ONR 6 CONR 6 -, R 6 2 NCONOR 7 -, and
  • R 6 CONOR 7 - wherein each R 6 is independently H or lower alkyl (1-4C); R 7 is H, lower alkyl (1-4C) or an acyl group, and
  • Alkyl has its conventional meaning as a straight chain, branched chain or cyclic saturated hydrocarbyl residue such as methyl, ethyl, isobutyl, cyclohexyl, t-butyl or the like.
  • the alkyl substituents of the invention are of the number of carbons noted which may be substituted with 1 or 2 substituents. Substituents are generally those which do not interfere with the activity of the compound, including hydroxyl, CBZO-, CBZNH-, amino, and the like.
  • Aryl refers to aromatic ring systems such as phenyl, naphthyl, pyridyl, quinolyl, indolyl, and the like; aryl alkyl refers to aryl residues linked to the position indicated through an alkyl residue. In all cases the aryl portion may be substituted or unsubstituted.
  • "Acyl” refers to a substituent of the formula RCO- wherein R is alkyl or arylalkyl as above-defined. The number of carbons in the acyl group is generally 1-15; however as the acyl substitute is readily hydroxylized in vivo the nature of the group is relatively unimportant.
  • Cyclic amines refer to those amines where the nitrogen is part of a heterocyclic ring, such as piperidine, "heterocyclic amines” refer to such heterocycles which contain an additional heteroatom, such as morpholine.
  • R 3 are H and methyl, especially H.
  • R 4 is a fused or conjugated bicyclo aromatic system linked through a methylene group to the molecule.
  • fused or conjugated bicyclo aromatic system is meant a two-ringed system with aromatic character which may, further, contain one or more heteroatoms such as S, N, or O. When a heteroatom such as N is included, the system as it forms a part of formulas 1-4, may contain an acyl protecting group (1-5C) attached to the nitrogen.
  • Representative bicyclo fused aromatic systems include naphthyl, indolyl, quinolinyl, and isoquinolinyl.
  • Representative conjugated systems include biphenyl, 4-phenylpyrimidyl, 3-phenylpyridyl and the like.
  • any available position of the fused or conjugated bicyclic system can be used for attachment through the methylene.
  • the fused or conjugated aromatic system may further be substituted by 1-2 alkyl (1-4C) residues and/or hydroxy or any ring nitrogens may be acylated.
  • Preferred acylation is acetylation.
  • R 4 Preferred embodiments of R 4 include 1-(2-methyl naphthyl)methylene; 1-quinolyl methylene; 1-naphthyl methylene; 2-naphthyl methylene; 1-isoquinolyl methylene; 3- isoquinolyl methylene; 3-thionaphthenyl methylene; 3-cumaronyl methylene; 3-(5- methylindolyl)methylene; 3-(5-hydroxyindolyl)methylene; 3-(2- hydroxyindolyl)methylene; biphenyl methylene; and 4-phenylpyrimidyl methylene; and the substituted forms thereof.
  • R 4 is 3-indolylmethylene or its N- acylated derivative—i.e., that embodiment wherein the "C-terminal" amino acid is a tryptophan residue or a protected form thereof.
  • a preferred configuration at the carbon to which R 4 is bound is that corresponding to L-tryptophan.
  • Preferred embodiments of X are those of the formula NHR 5 wherein R 5 is H, substituted or unsubstituted alkyl (1-12C) or aryl alkyl (6-12C). Particularly preferred substitutions on R 5 are a hydroxyl group, or a phenylmethoxycarbamyl (CBZNH-) residue.
  • R 5 is H, substituted or unsubstituted alkyl (1-12C) or aryl alkyl (6-12C).
  • Particularly preferred substitutions on R 5 are a hydroxyl group, or a phenylmethoxycarbamyl (CBZNH-) residue.
  • the compound may be extended by embodiments wherein X is an additional amino acid residue, particularly a glycyl residue, which may also be amidated as described.
  • the compounds that are hydroxamates are obtained by converting a carboxylic acid or ester precursor of the formulas
  • R is H or alkyl (1-6C) to the corresponding hydroxamates by treating these compounds or their activated forms with hydroxylamine under conditions which effect the conversion.
  • the components forming the -NR 3 -CHR 4 COX moiety are readily available in the case of tryptophan and its analogs as esters or amides.
  • many analogous fused bicyclo aromatic amino acids are described by Greenstein and Winitz (supra).
  • Amino acids corresponding to those wherein R 4 is 1-(2-methyl naphthyl)methylene; 1-quinolyl-methylene; 1-naphthyl methylene; 1-isoquinolyl methylene; and 3-isoquinolyl methylene can be prepared from the bicyclo aromatic methylene halides using the acetamido malonic ester synthesis of amino acids, as is well understood in the art.
  • the methylene halides themselves can be prepared from their corresponding carboxylic acids by reduction with hthium aluminum hydride and bromination of the resulting alcohol with thionyl bromide.
  • the hydroxylamine reagent is formed in situ by mixing the hydroxylamine hydrochloride salt with an excess of KOH in methanol and removing the precipitated potassium chloride by filtration.
  • the filtrate is then stirred with the precursor activated carboxylic acid or ester of formula 5 or 6 for several hours at room temperature, and the mixture is then evaporated to dryness under reduced pressure.
  • the residue is acidified, then extracted with a suitable organic solvent such as ethyl acetate, the extract washed with aqueous potassium bisulfate and salt, and then dried with a solid drying agent such as anhydrous magnesium sulfate.
  • the extract is then again evaporated to dryness and crystallized.
  • H 2 NOR 7 wherein R 7 is lower alkyl or acyl (1-4C) for hydroxylamine per se.
  • the resulting O-alkyl or acyl hydroxamate can then be further alkylated, if desired, to obtain the R 7 ONR 6 - derivative of the carboxylic acid.
  • HNR 6 OH may be reacted with the carboxylic acid to obtain the HONR 6 - derivative.
  • HNCH 3 OH and H 2 NOCH 3 are commercially available.
  • NHR 3 CHR 4 COX wherein X is other than OH under conditions wherein the condensation to form the amide bond occurs.
  • Such conditions typically comprise mixture of the two components in a nonaqueous anhydrous polar aprotic solvent in the presence of base and a condensing agent such as a carbod ⁇ mide.
  • a condensing agent such as a carbod ⁇ mide.
  • the formation of the amide linkage can be catalyzed in the presence of standard dehydration agents such as the carbodiimides, for example dicyclohexyl carbodiimide, or N, N-carbonyl diimidazole.
  • the product is then recovered as a mixture of diastereomers of formula 5 or 6.
  • This mixture is preferably used for the conversion to the hydroxamate and one of the resulting diastereomers is crystallized directly from the product mixture.
  • the diastereomers are separated by flash chromatography before conversion to the hydroxamate and recovered separately. This process is less preferred as compared to the process wherein separation of the diastereomers is reserved until the final product is obtained.
  • the "A" isomer is defined as that which migrates faster on TLC; the “B” isomer as that which migrates more slowly.
  • the "L” form of tryptophan or other amino acid containing a fused bicycloaromatic ring system is used as the residue, and R 1 is H
  • the "A” form is that which contains the corresponding configuration at the carbon containing the R 2 substituent (providing that is the only other center of asymmetry) in the final hydroxamate product.
  • the "B” isomer contains what would correspond to an "L” configuration at the carbon containing R 2 in the compounds of formula 1.
  • the corresponding O- or N-alkyl hydroxylamine is reacted with the methyl ester 4A as performed for unsubstituted hydroxylamine in Example 1.
  • the methyl ester 4A can be saponified to its corresponding carboxylic acid and activated with oxalyl chloride or other condensing agent.
  • the alkyl hydroxylamine can then be reacted with the activated carboxylic acid to give the O- or N-substituted hydroxamic acid.
  • O- and N-methylhydroxylamine can be purchased from the Aldrich Chemical Company.
  • N-alkyl hydroxylamines can be synthesized by conversion of aliphatic aldehydes to their oximes, followed by reduction to the N-alkyl hydroxylamine with borane-pyridine complex in the presence of 6N HCl (Kawase, M. and Kikugawa, Y.J., Chem Soc, Perkin Trans (1979) 1:643.
  • Other O-alkyl hydroxylamines can be synthesized by the general methods given by Roberts, J.S., "Derivatives of
  • a hydroxamic acid of this invention can be acylated with an acid chloride, anhydride, or other acylating agent to give the compounds of this class.
  • Preferred compounds of formula (1) or (2) include: HONHCOCH 2 CH(n-hexyl)-CO-L-Trp-NHMe;
  • the components forming the -NR 3 -CHR 4 COX moiety are readily available in the case of tryptophan and its analogs as esters or amides.
  • many analogous fused bicyclo aromatic amino acids are described by Greenstein and Winitz (supra).
  • Amino acids corresponding to those wherein R 4 is 1-(2-methyl naphthyl)methylene; 1-quinolyl-methylene; 1-naphthyl methylene; 1-isoquinolyl methylene; and 3-isoquinolyl methylene can be prepared from the bicyclo aromatic methylene halides using the acetamido malonic ester synthesis of amino acids, as is well understood in the art.
  • the methylene halides themselves can be prepared from their corresponding carboxylic acids by reduction with lithium aluminum hydride and bromination of the resulting alcohol with thionyl bromide.
  • the compounds are prepared by acylating an ⁇ , ⁇ or ⁇ amino acid, respectively with methyl or ethyl chloroformate, condensing the resulting amino acid with a protected form of the moiety -NR 3 CHR 4 COX and reacting the resulting carboethoxy "dipeptide" with hydroxylamine or a substituted hydroxylamine as described by Fieser, L.F., et al., "Reagents for Organic Synthesis” (1967) L479 (John Wiley & Sons, New York). This sequence of reactions is shown in Reaction Scheme 1A.
  • the ⁇ , ⁇ or ⁇ amino acid is temporarily protected using, for example, carbobenzoxy or tertiary butyloxycarbonyl and coupling it to the carboxy- terminal-protected amino acid moiety containing R 4 .
  • the protecting group is then removed by hydrogenolysis or acidolysis as appropriate, and the deprotected ⁇ , ⁇ or ⁇ amino group is reacted with an activated carbonic acid such as carbonyldiimidazole.
  • the resultant is then reacted with hydroxylamine or substituted hydroxylamine to obtain the desired product.
  • Reaction Scheme 2 In the formula Im-Co-Im, Im represents an imidazole residue.
  • Such methods include, for example, homologation by Arndt-Eistert synthesis of the corresponding N- protected ⁇ -amino acid and more generally the addition of nitrogen nucleophiles such as phthalimide to ⁇ , ⁇ -unsaturated esters, acids or nitriles.
  • Y has the formula R 6 2 NCONOR 7 - and n is 0, 1 or 2. These compounds are prepared from the corresponding ⁇ , ⁇ or ⁇ hydroxyamino acids of the formula R 7 ONH(CHR 1 ) n CHR 2 COOH. When both R 6 are H, this
  • the ⁇ -N-hydroxyamino acids used as intermediates in the foregoing synthesis can be prepared by a malonic ester synthesis in which diethyl malonate is alkylated twice, one with R 2 -Br and then with benzylchloromethyl ether, for example, for the case wherein R 1 is H.
  • the product is saponified, decarboxylated, hydrogenated, and oxidized to give the ⁇ -aldehyde in a manner similar to the synthesis of a homologous aldehyde described by Kortylewicz, Z.P., et al., Biochemistry (1984) 23:2083-2087.
  • the desired ⁇ -hydroxyamino acid is then obtained by addition of protected (or alkylated, if R 7 is alkyl or acylated if R7 is acyl) hydroxylamine.
  • protected (or alkylated, if R 7 is alkyl or acylated if R7 is acyl) hydroxylamine is then obtained by addition of protected (or alkylated, if R 7 is alkyl or acylated if R7 is acyl) hydroxylamine.
  • R 1 is alkyl
  • the homologous ketone was described by Galardy, R.E., et al., Biochemistry (1985) 24:7607-7612.
  • those compounds wherein Y is of the formula R 6 CONOR 7 - can be prepared by acylation of the corresponding ⁇ , ⁇ or ⁇ N- hydroxy dipeptide.
  • the N-hydroxyamino acid can be acylated, followed by condensation to form the amide bond in the compounds of the invention.
  • the acylation method is described by, for example, Nishino, N., et al., Biochemistry (1979) 18:4340-4346, cited above.
  • the compounds can be prepared by condensing the ylide 1,1-dimethoxy-2-(triphenylphosphoranylidene) ethane prepared from triphenylphosphine and 1,1-dimethoxy-2-bromoethane with 4- methyl-2-oxopentanoic acid. The product is then hydrogenated to obtain 4,4-dimethoxy- 2-isobutylbutanoic acid which is coupled to the moiety R 3 NHCHR 4 COX to obtain 4,4- dimethoxy-2-isobutylbutanoyl-NR 3 CHR 4 COX.
  • Preferred compounds of formulas (3) and (4) include:
  • a number of diseases are known to be mediated by excess or undesired matrix-destroying metalloprotease activity. These include tumor metastasis, rheumatoid arthritis, skin inflammation, ulcerations, particularly of the cornea or mouth, reaction to infection, and the like.
  • Also intended to come within the definition of diseases that can be treated by the invention inhibitors are wounds, preferably chronic dermal wounds.
  • the inhibitors of the invention are, however, useful in any ulcerative skin condition, including, for example, decubitus ulcers, ulcers of me mouth, or other conditions where wound healing is slow.
  • the compounds of the invention are useful in therapy with regard to conditions involving this unwanted activity.
  • Psoriasis is a common inflammatory skin disease of uncertain etiology, which is characterized by prominent epidermal hyperplasia, mixed
  • Still another condition responsive to the matrix metalloprotease inhibitors of the invention, particularly collagenase inhibitors, include restenosis following angioplasty.
  • the healthy arterial wall is composted of an outer adventitial layer of fibroblasts, a central medial layer of smooth muscle cells and a luminal intimal layer of endothelial cells. It has been postulated that one cause of restenosis following balloon angioplasty is the production and release of collagenase by smooth muscle cells that causes
  • matrix metalloprotease inhibitors of the invention would prevent or inhibit restenosis when administered before or after angioplasty.
  • Yet another application of the matrix metalloprotease inhibitors of the invention is the treatment or prevention of cancer, particularly metastatic cancer. Cancer cells migrate from their primary site of origin to remote secondary sites by extravasation into the blood, and subsequent extravasation out of the blood to the target organ. Thus, it would be possible to prevent or eliminate metastasis if extravasation of cancer cells could be controlled. Since a key process in extravasation is the breakdown of the extracellular matrix by enzymes secreted by cancer cells, particularly collagenases, the collagenase inhibitors of the invention have significant applications for the treatment or prevention of cancer.
  • the collagenase inhibitors of the invention are useful in any ulcerative skin condition, including, for example, decubitus ulcers, ulcers of the mouth, or other conditions where wound healing is slow.
  • Similar conditions susceptible to treatment by the compounds of the invention include corneal or scleral melting associated with keratomalacia, scleromalacia perforans and connective tissue diseases.
  • An example of the latter is keratoconus which involves thinning and central
  • Type IV collagenase is thought to be responsible, at least in part, for the disease.
  • Compounds which are synthetic inhibitors of mammalian metalloproteases are useful to inhibit angiogenesis. These compounds can therefore be formulated into pharmaceutical compositions for use in inhibiting angiogenesis in conditions
  • Standard pharmaceutical formulation techniques are used, such as those disclosed in Remington's Pharmaceutical Sciences, Mack Pubhshing Company, Easton, PA, latest edition.
  • the compounds be injected. These conditions include tumor growth and metastasis.
  • the compounds can be formulated for injection using excipients conventional for such pmpose such as physiological saline, Hank's solution, Ringer's solution, and the like. Injection can be intravenous, intramuscular, intraperitoneal or subcutaneous. Dosage levels are of the order of 0.1 mg/kg of subject to 100 mg/kg of subject, depending, of course, on the nature of the condition, the nature of the subject, the particular embodiment of the invention compounds chosen, and the nature of the formulation and route of
  • the compounds of the invention can also be formulated into compositions for transdermal or transmucosal delivery by including agents which effect penetration of these tissues, such as bile salts, fusidic acid derivatives, cholic acid, and the like.
  • the compounds can also be used in liposome- based delivery systems and in formulations for topical and oral administration depending on the nature of the condition to be treated. Oral administration is especially advantageous for those compounds wherein the moiety -CONR 3 - is in a modified isosteric form. These compounds resist the hydrolytic action of the digestive tract.
  • Oral formulations include syrups, tablets, capsules, and the like, or the compound may be administered in food or juice.
  • the inhibitors of the invention can be targeted to specific locations where vascularization occurs by using targeting ligands.
  • the inhibitor is conjugated to an antibody or fragment thereof which is immunoreactive with a tumor marker as is generally understood in the preparation of immunotoxins in general.
  • the targeting ligand can also be a ligand suitable for a receptor which is present on the tumor. Any targeting ligand which specifically reacts with a marker for the intended target tissue can be used. Methods for coupling the compounds to the targeting ligand are well known and are similar to those described below for coupling to carrier.
  • the conjugates are formulated and administered as described above.
  • topical administration is preferred.
  • direct application to the affected eye may employ a formulation as eyedrops or aerosol.
  • the compounds of the invention can also be formulated as gels or ointments, or can be incorporated into collagen or a hydrophilic polymer shield.
  • the materials can also be inserted as a contact lens or reservoir or as a subconjunctival formulation.
  • the compounds of the invention can be administered alone or as mixtures, and the compositions may further include additional drugs or excipients as appropriate for the indication.
  • Conditions that benefit from angiogenesis inhibition thus include, generally, cancer, including angiosarcoma, Kaposi's sarcoma, glioblastoma multiforme,
  • hemangioblastoma including von Hippel-Lindan disease and hemangiopericytoma
  • eye conditions such as diabetic retinopathy and neovascular glaucoma
  • immune system conditions such as rheumatoid arthritis, angiolymphoid hyperplasia with eosinophilia
  • skin conditions such as cavernous hemangioma (including Kasabach-Merritt syndrome) and psoriasis.
  • TLC solvent systems are as follows: (A) ethyl acetate/methanol (95:5); (B) ethyl acetate/methanol (25:5); (C) ethyl acetate; (D) ethyl acetate/methanol (30:5); (E) ethyl acetate/hexane (1:1); (F) chloroform/me thanol/acetic acid (30:6:2); (G) chloroform/methanol/acetic acid (85:10:1).
  • Isomers 4A and 4B were separated by flash chromatography (silica gel, ethyl acetate).
  • the 5A can be crystallized directly from the residue as described above.
  • the corresponding compounds of formula 1 are prepared wherein R 1 is H and R 2 is an n-propyl, i-propyl, n-butyl, 2- methylbutyl, and n-octyl, respectively.
  • R 1 is H and R 2 is an n-propyl, i-propyl, n-butyl, 2- methylbutyl, and n-octyl, respectively.
  • the corresponding compounds of formula 2 wherein R 1 is H and R 2 is as set forth above are obtained.
  • the intermediate ester of formula 3 or 4 is deesterified and acylated prior to conversion to the hydroxamate.
  • 4A is deesterified with sodium hydroxide in ethanol and then acidified to give N-(L-2-isobutyl-3-carboxypropanoyl)-L-tryptophan methylamide, which is treated with the anhydride of an alkyl (1-4C) carboxylic acid to obtain N-(L-2-isobutyl-3-carboxypropanoyl)-L-((N-acyl)indolyl)-tryptophan
  • the hydrochloride salt of L-tryptophan amylamide was prepared as described in Example 1 for L-tryptophan methylamide and was reacted with 3 that had been activated with 1,1'-carbonyldiimidazole for 20 minutes in dichloromethane at room temperature.
  • the mixture of the two diastereomers of N-[D,L-2-isobutyl-3- (methoxycarbonyl)-propanoyl]-L-tryptophan amylamide 14A,B (90% yield) was converted to its corresponding hydroxamic acids as described for 4A. Slow evaporation of the ethylacetate solution gave 0.343 g (71%) of 15A,B: mp 160-163°C. MS-FAB (m/z) 445 (M + + H).
  • the compound 25A was converted to N-[L-2-isobutyl-3- methoxycarbonylpropanoyl]-L-tryptophan (6-phenylmethoxycarbonylamino-hexyl- l)amide (26A) as follows. A mixture of 0.55 g (1.47 mmol) of 25A and 0.24 g (1.48 mmol) of CDI in 1 mL of 2% dimethylformamide in methylene chloride was stirred for 0.5 hr at room temperature and 0.42 g (1.47 mmol) of 23 was added.
  • TPA 12-0-tetradecanoylphorbol-13-acetate
  • the phorbol ester, PdiBu (20 nmol in 20 ⁇ l if acetone) was applied to both ears of hairless mice (Hr/Hr) (approximately 1 cm 2 each).
  • the test compounds (in total volume of 20 ⁇ l) were then applied to the right ear immediately (15 to 30 min) following PdiBu.
  • the left ear of each animal received an equivalent amount (20 ⁇ l) of vehicle.
  • Test compounds (and vehicle) were reapplied at 6 and 18 hours following PdiBu. Treatment times were staggered to allow exact time intervals to be obtained.
  • animals were anesthetized, and ear thickness values were obtained using a microcaliper.
  • the weights of punch biopsies (6mm) were then obtained. Histology was performed on selected samples taken at 30 hours.
  • Test compounds included GM6001 (10mg/ml in ETOH), a negative control, acetohydroxamic acid (AHA; 2mg/ml in ETOH), and fluocinonide (Lidex R ) as a positive control (0.05% in vehicle of alcohol [35%], diisopropyl adipate, citric acid and propylene glycol).
  • the controls for this series include: 1) Untreated controls; 2) PdiBu plus vehicle alone (included for each mouse tested); 3) PdiBu plus AHA; 4) PdiBu plus Lidex R as a positive control.
  • AHA Control Topical AHA (0.53 ⁇ mol/ear applied at each of three timepoints: 0.25, 6.0, and 24 hours) did not alter the PdiBu-induced increase in ear thickness and biopsy weight:
  • Lidex R fluocinonide
  • GM6001 demonstrated potent anti-inflammatory activity in this standard in vivo model for psoriasis.
  • the extent of anti-inflammatory activity was nearly comparable to that observed with Lidex R , the positive control.
  • the reduction of PdiBu-induced ear weight was accompanied by similar inhibition of ear thickening.
  • decreased inflammation and epidermal hyperplasia were evident by histologic analysis.
  • Acetohydroxamic acid (AHA) was used as a negative control since it is devoid of inhibitory effects on MMPs. It did not alter PdiBu-induced effects on ear thickness or weight.
  • the fluids were centrifuged, and the supernatants filtered using a 0.45 u sterile Gelman filter. The filtrates were stored frozen at -80°C until tested for protease activity.
  • the effects of four inhibitors on the protease activity present in wound fluids were determined.
  • the inhibitors were: compound 5 A, also termed GM 6001
  • GM6001 was dissolved in an amount of warmed propylene glycol to give a final concentration of 2.4%, then dissolved in 10mM citrate, pH 5.5, containing 0.55% methyl cellulose.
  • S1209 was dissolved in 1% DMSO then dissolved in lOmM citrate, pH 5.5, containing 0.05% methyl cellulose.
  • GM1489 was dissolved in propylene glycol (to give a final concentration of 2.4%) then dissolved in 1 mM CaCl 2 , 50 mM Tris-Cl, pH 7.8.
  • GM1339 was dissolved in propylene glycol (2.4%) methyl cellulose (0.05%) and 10 mM citrate, pH 8.
  • the protease substrate, Azocoll was obtained from Sigma Chemical
  • Clostridium histolyticum collagenase (the crude form of the enzyme) was from Worthington Biochemicals.
  • General chemicals including TRIS buffer, DMSO, and CaCl 2 were from Sigma Chemical Corporation.
  • 900 ⁇ l of the Azocoll substrate suspension in buffer (5 ⁇ g/ml in 50 mM TRIS, pH 7.8, ImM CaCl 2 ) was added to 1.5ml microcentrifuge tubes then 50 ⁇ l of inhibitor (or buffer) and 50 ⁇ l of chronic wound fluid (or collagenase standard) were added to the reaction tube.
  • the reaction tubes were placed at 37°C in a shaker that inverted the tubes 30 times per minute. After 24 hours of incubation, the reaction tubes were centrifuges at 10,000 X g and the absorbance of the supernatant solution was measured at 520 nm with a Milton-Roy spectrophotometer.
  • Proteolysis of Azocoll substrate generates soluble colored fragments from the insoluble Azocoll substrate.
  • Wound fluid samples were incubated alone or with the inhibitors. Controls included incubation of the Azocoll substrate with the assay buffer to measure spontaneous degradation of the substrate.
  • a standard curve for digestion of the Azocoll substrate was generated by incubation of the Azocoll with crude bacterial collagenase.
  • Protease levels were expressed as net ⁇ g of collagenase equivalent per ml of chronic wound fluid. In the figures, certain of the wound fluids are referred to by an individual name.
  • FIG. 2 shows the results.
  • Mastectomy fluid samples collected on days 1 to 7 after surgery contained low levels of protease activity with an average of 0.75 ⁇ 0.06 ⁇ g equivalents of collagenase/ml of wound fluid.
  • figure 3 shows that wound fluids collected from open wounds contained an average protease level of 199 ⁇ 59 ⁇ g/ml of wound fluid, and fluids collected from chronic wounds contained an average protease level of 125 ⁇ 95 ⁇ g/ml.
  • Only one of the thirteen samples of fluids, L. Smith, from chronic or open wounds did not contain measurable levels of Azocoll hydrolysis activity.
  • the protease levels of the remaining twelve samples of open and chronic wounds were all higher than the levels measured in mastectomy fluids and ranged from 2 to 585 ⁇ g/ml wound fluid.
  • fluids collected from chronic and open wounds contain very high levels of Azocoll-degrading protease activity compared to fluid collected from mastectomy drains. This suggests that the in vivo environment of open or chronic wounds contains proteases that have the ability to degrade extracellular matrix proteins of wounds.
  • GM6001 very effectively inhibited proteolytic degradation of Azocoll (approximately 96% of initial proteolytic activity) by a chronic wound fluid when added at final concentrations of 40 ⁇ g/ml (100 ⁇ M) or 4 ⁇ g/ml (10 ⁇ M).
  • GM6001 and EDTA were very effective inhibitors while PMSF did not significantly reduce proteolytic activity of the wound fluids.
  • GM6001 and EDTA consistently reduced proteolytic activity by 95% in open or chronic wound fluids with high levels of Azocoll-degrading protease activity.
  • PMSF did not reduce the levels of proteolytic activity. This supports the general concept that open and chronic wounds consistently have elevated levels of matrix metalloproteinases which can effectively be inhibited by GM6001.
  • GM6001 and SI 209 are very effective inhibitors of Azocoll-degrading proteases in a larger series of wound fluids.
  • MP506 was a somewhat less effective inhibitor than GM6001 or S1209.
  • GM6001 was dissolved in an amount of warmed propylene glycol to give a final concentration of 2.4%, then dissolved in 10 mM citrate, pH 5.5, containing 0.05% methyl cellulose.
  • S1209 was dissolved in 1% DMSO then dissolved in 10mM citrate, pH 5.5, containing 0.05% methyl cellulose.
  • GM1489 was dissolved in propylene glycol (to give a final concentration of 2.4%) then dissolved in 1 mM CaCl 2 , 50 m Tris-Cl, pH 7.8.
  • GM1339 was dissolved in propylene glycol (2.4%) metiiyl cellulose (0.05%) and 10 mM citrate, pH 8.
  • the chronic wound fluid contained a high level of protease activity with an average of 284 ⁇ 52 ⁇ g collagenase equivalents/ml of wound fluid.
  • Addition of GM6001 at 800 ⁇ g/ml reduced the level of protease activity by 84% to 45 ⁇ 1 ⁇ g collagenase equivalents/ml of wound fluid.
  • Lower concentrations of GM6001 resulted in slighdy higher levels of protease activity up to 90 ⁇ 6 ⁇ g collagenase equivalents/ml of wound fluid.
  • GM1339 and S1209 also effectively inhibited the protease activity of the chronic wound fluid, with the highest concentration (800 ⁇ g/ml) inhibiting 94% and 70%, respectively (see Table 1).
  • concentration 800 ⁇ g/ml
  • GM1489 only inhibited 23% of the protease activity, and 13% and 30% increases were measured at the 8 ⁇ g/ml and 0.8 ⁇ g/ml concentrations.
  • GM1489 was significantly less potent that GM6001, GM1339, or S1209. and lower concentrations of GM1489 actually increased the level of proteolytic activity of the chronic wound fluid.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des procédés et des compositions efficaces pour le traitement ou la prévention de maladies, telles que des maladies de la peau, le kératoconus, la resténose ou des blessures, et les compositions comprennent des inhibiteurs synthétiques de la métalloprotéase de matrice chez les mammifères.
PCT/US1994/003600 1993-04-07 1994-04-01 Inhibiteurs synthetiques de la metalloprotease de matrice et utilisations WO1994022309A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP94913345A EP0692931A4 (fr) 1993-04-07 1994-04-01 Inhibiteurs synthetiques de la metalloprotease de matrice et utilisations
AU65542/94A AU6554294A (en) 1993-04-07 1994-04-01 Synthetic matrix metalloprotease inhibitors and uses thereof
JP6522412A JPH08511509A (ja) 1993-04-07 1994-04-01 合成マトリックスメタロプロテアーゼ阻害剤およびその用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4432493A 1993-04-07 1993-04-07
US08/044,324 1993-04-07

Publications (1)

Publication Number Publication Date
WO1994022309A1 true WO1994022309A1 (fr) 1994-10-13

Family

ID=21931747

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/003600 WO1994022309A1 (fr) 1993-04-07 1994-04-01 Inhibiteurs synthetiques de la metalloprotease de matrice et utilisations

Country Status (5)

Country Link
EP (1) EP0692931A4 (fr)
JP (1) JPH08511509A (fr)
AU (1) AU6554294A (fr)
CA (1) CA2160139A1 (fr)
WO (1) WO1994022309A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0684240A1 (fr) * 1994-04-25 1995-11-29 F. Hoffmann-La Roche Ag Dérivés de l'acide hydroxamique substitués par trois cycles
WO1996016027A1 (fr) * 1994-11-22 1996-05-30 Syntex (U.S.A.) Inc. Inhibiteurs des metalloproteases matricielles
WO1998016506A1 (fr) * 1996-10-16 1998-04-23 American Cyanamid Company Acides beta-sulfonamido hydroxamiques utilises comme inhibiteurs de metalloproteases matricielles et de tace
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
US6172064B1 (en) 1998-08-26 2001-01-09 Glaxo Wellcome Inc. Formamides as therapeutic agents
US6191150B1 (en) 1998-08-26 2001-02-20 Glaxo Wellcome Inc. Formamide compounds as therapeutic agents
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
US6329400B1 (en) 1998-08-26 2001-12-11 Glaxo Wellcome Inc. Formamide compounds as therapeutic agents
WO2001089502A3 (fr) * 2000-05-22 2003-01-03 Univ Michigan Compositions et procedes a utiliser contre l'inflammation induite par l'acne et les enzymes degradant la matrice dermique
US6569664B1 (en) 1996-11-06 2003-05-27 The Regents Of The University Of California Native TNF receptor releasing enzyme
EP1372692A2 (fr) * 2001-03-19 2004-01-02 Sloan Kettering Institute For Cancer Research Synthese asymetrique de (s,s,r)-(-)-actinonine, de ses analogues et ses utilisations
US7892825B2 (en) 2003-08-08 2011-02-22 Arriva Pharmaceuticals, Inc. Method of protein production in yeast
US7914771B2 (en) 2004-03-09 2011-03-29 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9903598D0 (en) * 1999-02-18 1999-04-07 Univ Manchester Connective tissue healing
WO2009113320A1 (fr) * 2008-03-13 2009-09-17 株式会社ヤクルト本社 Inhibiteur de mmp
JP2015517575A (ja) * 2012-05-21 2015-06-22 ディーシービー−ユーエスエー エルエルシーＤｃｂ−Ｕｓａ Ｌｌｃ ゼブラフィッシュモデルを用いることにより薬物をスクリーニングする方法、及びこの方法によりスクリーニングされた化合物

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
EP0320118A2 (fr) * 1987-11-14 1989-06-14 Beecham Group Plc Peptides à activité inhibant la collagénase
US4918105A (en) * 1987-01-06 1990-04-17 Sa Laboratoire Roger Bellon Novel compounds with collagenase-inhibiting activity, a process for their preparation and pharmaceutical compositions in which these compounds are present
WO1991017982A1 (fr) * 1990-05-21 1991-11-28 Sankyo Company, Limited Nouveau compose de matristatine
US5114953A (en) * 1990-11-21 1992-05-19 University Of Florida Treatment for tissue ulceration
US5268384A (en) * 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
US5270326A (en) * 1990-11-21 1993-12-14 University Of Florida Treatment for tissue ulceration

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5239078A (en) * 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
EP0489577B1 (fr) * 1990-12-03 1995-03-22 Celltech Limited Dérivés peptidyliques

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US4918105A (en) * 1987-01-06 1990-04-17 Sa Laboratoire Roger Bellon Novel compounds with collagenase-inhibiting activity, a process for their preparation and pharmaceutical compositions in which these compounds are present
EP0320118A2 (fr) * 1987-11-14 1989-06-14 Beecham Group Plc Peptides à activité inhibant la collagénase
WO1991017982A1 (fr) * 1990-05-21 1991-11-28 Sankyo Company, Limited Nouveau compose de matristatine
US5114953A (en) * 1990-11-21 1992-05-19 University Of Florida Treatment for tissue ulceration
US5268384A (en) * 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
US5270326A (en) * 1990-11-21 1993-12-14 University Of Florida Treatment for tissue ulceration

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
E.M. FARBER et al., "PSORIASIS. Proceedings of the Fourth International Symposium", published 1987 by Elsevier (New York), pages 119-122, see especially page 121. *
Res. Exp. Med., Vol. 185, 1985, H. HOGSTROM et al., "Early Decrease in Suture Line Breaking Strength. The Proposed Collagenase Inhibition", pages 451-455, see entire document. *
See also references of EP0692931A4 *
Tetrahedron Letters, Vol. 34, No. 4, issued 1993, K. TAMAKI et al., "Synthesis and Determination of the Absolute Configuration of Matlystatin B", pages 683-686, see entire document. *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614625A (en) * 1994-04-25 1997-03-25 Hoffmann-La Roche Inc. Hydroxamic acid derivatives with tricyclic substitution
US5698690A (en) * 1994-04-25 1997-12-16 Hoffmann-La Roche Inc. Hydroxamic acid derivatives with tricyclic substitution
US5710167A (en) * 1994-04-25 1998-01-20 Hoffmann-La Roche Inc. Hydroxamic acid derivatives with tricyclic substitution for treating degenerative joint diseases
US5731441A (en) * 1994-04-25 1998-03-24 Hoffmann-La Roche Inc. Hydroxamic acid derivatives with tricyclic substitution
EP0684240A1 (fr) * 1994-04-25 1995-11-29 F. Hoffmann-La Roche Ag Dérivés de l'acide hydroxamique substitués par trois cycles
WO1996016027A1 (fr) * 1994-11-22 1996-05-30 Syntex (U.S.A.) Inc. Inhibiteurs des metalloproteases matricielles
CN1105101C (zh) * 1996-10-16 2003-04-09 美国氰胺公司 作为基质金属蛋白质酶和TACE抑制剂的β－亚磺酰氨基异羟肟酸
WO1998016506A1 (fr) * 1996-10-16 1998-04-23 American Cyanamid Company Acides beta-sulfonamido hydroxamiques utilises comme inhibiteurs de metalloproteases matricielles et de tace
US6569664B1 (en) 1996-11-06 2003-05-27 The Regents Of The University Of California Native TNF receptor releasing enzyme
US6573062B1 (en) 1996-11-06 2003-06-03 The Regents Of The University Of California Method for obtaining modulators of TNF receptor releasing enzyme
US6858402B2 (en) 1996-11-06 2005-02-22 The Regents Of The University Of California System for discovering and producing polypeptides that cause TNF receptor shedding
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
US6329400B1 (en) 1998-08-26 2001-12-11 Glaxo Wellcome Inc. Formamide compounds as therapeutic agents
US6172064B1 (en) 1998-08-26 2001-01-09 Glaxo Wellcome Inc. Formamides as therapeutic agents
US6191150B1 (en) 1998-08-26 2001-02-20 Glaxo Wellcome Inc. Formamide compounds as therapeutic agents
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
WO2001089502A3 (fr) * 2000-05-22 2003-01-03 Univ Michigan Compositions et procedes a utiliser contre l'inflammation induite par l'acne et les enzymes degradant la matrice dermique
EP1372692A2 (fr) * 2001-03-19 2004-01-02 Sloan Kettering Institute For Cancer Research Synthese asymetrique de (s,s,r)-(-)-actinonine, de ses analogues et ses utilisations
EP1372692A4 (fr) * 2001-03-19 2005-10-26 Sloan Kettering Inst Cancer Synthese asymetrique de (s,s,r)-(-)-actinonine, de ses analogues et ses utilisations
US7892825B2 (en) 2003-08-08 2011-02-22 Arriva Pharmaceuticals, Inc. Method of protein production in yeast
US7914771B2 (en) 2004-03-09 2011-03-29 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor

Also Published As

Publication number Publication date
EP0692931A1 (fr) 1996-01-24
EP0692931A4 (fr) 1996-03-20
CA2160139A1 (fr) 1994-10-13
JPH08511509A (ja) 1996-12-03
AU6554294A (en) 1994-10-24

Similar Documents

Publication Publication Date Title
US5773438A (en) Synthetic matrix metalloprotease inhibitors and use thereof
US5696147A (en) Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
US5239078A (en) Matrix metalloprotease inhibitors
US5189178A (en) Matrix metalloprotease inhibitors
EP0558681B1 (fr) Traitement contre les ulcerations tissulaires
US5183900A (en) Matrix metalloprotease inhibitors
AU6554294A (en) Synthetic matrix metalloprotease inhibitors and uses thereof
US5270326A (en) Treatment for tissue ulceration
AU5778601A (en) Synthetic matrix metalloprotease inhibitors and uses thereof
AU8311898A (en) Synthetic matrix metalloprotease inhibitors and uses thereof
AU1000399A (en) Synthetic matrix metalloprotease inhibitors and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP NO

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)

Free format text: NO

WWE Wipo information: entry into national phase

Ref document number: 2160139

Country of ref document: CA

Ref document number: 1994913345

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994913345

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1994913345

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994913345

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载